Synapse

← Cancer Drug Resistance

Papers in Cancer Drug Resistance

Page 1 · newest first

  1. PLA2G2A across tumor compartments and its relevance to drug resistanceCancer Drug Resistance · 2026
  2. PSMD14 as a translational target in cancer and beyond: from deubiquitination mechanisms to drug resistance and precision therapyCancer Drug Resistance · 2026
  3. Resistance to third-generation EGFR TKIs - what can be expected from the fourth-generation?Cancer Drug Resistance · 2026
  4. Bracing for the storm: emerging resistance mechanisms to KRAS inhibitors in pancreatic cancer and strategies to overcome themCancer Drug Resistance · 2026
  5. Adenylosuccinate lyase in pancreatic ductal adenocarcinoma chemoresistance: from purine metabolism to metabolic vulnerabilityCancer Drug Resistance · 2026
  6. Mitochondrial LINC01133 regulates pyroptosis and calcium homeostasis in cisplatin-resistant lung adenocarcinomaCancer Drug Resistance · 2026
  7. TET2 downregulation limits oxidative stress-induced cytotoxicity of high dose ascorbate in dabrafenib-resistant melanoma cellsCancer Drug Resistance · 2026
  8. Mechanistic roles and clinical applications of tertiary lymphoid structures in colorectal cancer drug resistanceCancer Drug Resistance · 2026
  9. An epithelial-mesenchymal transition-related gene signature predicts prognosis, immune infiltration, and drug sensitivity in colorectal cancerCancer Drug Resistance · 2026
  10. Lack of resolution of inflammation marks malignant pleural mesothelioma progressionCancer Drug Resistance · 2026
  11. LINC01607 promotes hepatocellular carcinoma progression and ferroptosis-associated therapy resistance with functional involvement of the p62–Keap1–Nrf2 pathwayCancer Drug Resistance · 2026
  12. Unveiling the role of UGT enzymes in chemoresistance: a path to enhanced cancer pharmacotherapyCancer Drug Resistance · 2026
  13. A systematic review and network meta analysis of first-line immunotherapy for advanced urothelial carcinomaCancer Drug Resistance · 2026
  14. Fenretinide in cancer therapy and chemoprevention: past, present and futureCancer Drug Resistance · 2026
  15. Deep spatial proteomics reveals a suppressive immune niche linked to immune evasion in renal cell carcinomaCancer Drug Resistance · 2026
  16. TRAP1 ablation improves mitochondrial cristae and oxidative phosphorylation in pancreatic cancer stem cellsCancer Drug Resistance · 2026
  17. Overcoming resistance to anti-PD-1/PD-L1 therapy in cancerCancer Drug Resistance · 2026
  18. Tumor heterogeneity as a driver of drug resistance and its implications for personalized therapyCancer Drug Resistance · 2026
  19. Novel N-chloroacetyl-2-pyrazoline analogs with 2-naphthyl and ferrocenyl groups: targeting histamine receptor H1 to overcome colorectal cancer drug resistanceCancer Drug Resistance · 2026
  20. Ultrasonic modulation of brain glymphatic transport: from observations to theranostic applicationsCancer Drug Resistance · 2026
  21. Nanomaterial-based strategies overcome PD-1 related intrinsic immune resistanceCancer Drug Resistance · 2026
  22. Paired single cell analysis reveals chemotherapy resistance in osteosarcomaCancer Drug Resistance · 2026
  23. Roles and potential applications of non-coding RNAs in cancer treatment with immune checkpoint inhibitors and immunomodulatory therapiesCancer Drug Resistance · 2026
  24. Immunotherapy resistance and strategies in malignant pleural mesotheliomaCancer Drug Resistance · 2026
  25. Multi-omics classification of acute myeloid leukemia guides drug combinations to overcome Venetoclax resistanceCancer Drug Resistance · 2026
  26. Conjugated oligoelectrolytes overcome cancer drug resistance by dual-mode lysosomal membrane disruptionCancer Drug Resistance · 2026
  27. From EGFR PTM network to TKI resistance: spatial subtypes and targeting in lung cancerCancer Drug Resistance · 2026
  28. TROP2-targeting antibody–drug conjugates in breast cancer and ovarian carcinoma: therapeutic advances and resistance mechanismsCancer Drug Resistance · 2026
  29. Extracellular vesicles shed by multidrug resistant cells contribute to the identification of SRC inhibitors as chemosensitizers in non-small cell lung cancerCancer Drug Resistance · 2026
  30. Novel anti-tumor strategies: targeting the crosstalk between cancer stem cells and cancer-associated fibroblasts to resist drug resistanceCancer Drug Resistance · 2026
  31. Identification of antibody-drug conjugate payloads that are substrates of ATP-binding cassette drug efflux transportersCancer Drug Resistance · 2026
  32. Circular RNA hsa-circ-0001030 suppresses proliferation and cisplatin tolerance in TSCC via interaction with PKM2Cancer Drug Resistance · 2026
  33. MicroRNAs as key regulators of cancer drug resistance: insights and future directions in chemotherapy, targeted-therapy, radiotherapy, and immunotherapyCancer Drug Resistance · 2025
  34. Unraveling resistance to immune checkpoint inhibitors in HNSCC: from mechanisms to combination therapiesCancer Drug Resistance · 2025
  35. Disrupting resistance: novel therapeutic approaches to combat multidrug resistance in fusion-negative rhabdomyosarcomaCancer Drug Resistance · 2025
  36. Overcoming cancer drug resistance through small-molecule targeting of HSP90 and HSP70Cancer Drug Resistance · 2025
  37. Mechanisms of resistance to antibody-drug conjugates in cancer therapy: molecular basis and therapeutic strategiesCancer Drug Resistance · 2025
  38. RCC1 knockdown sensitizes drug-resistant colorectal cancer to 5-fluorouracil or doxorubicin by impairing DNA repairCancer Drug Resistance · 2025
  39. Novel FAK inhibitors suppress tumor growth and reverse EGFR-TKI resistance in non-small cell lung cancerCancer Drug Resistance · 2025
  40. Circular RNA-based liquid biopsy: a promising approach for monitoring drug resistance in cancerCancer Drug Resistance · 2025
  41. Targeting tumor-draining lymph node to overcome resistance to cancer immunotherapy: an updateCancer Drug Resistance · 2025
  42. Recent progress on tyrosine kinase inhibitors resistance in renal cell carcinoma: another brick in the wall?Cancer Drug Resistance · 2025
  43. KLF5 promotes tumor proliferation and oxaliplatin resistance via chromatin remodeling in KRAS-mutated colorectal cancerCancer Drug Resistance · 2025
  44. CDK4/6 and BET inhibitors synergistically suppress pancreatic tumor growth and epithelial-to-mesenchymal transition by regulating the GSK3β-mediated Wnt/β-catenin pathwayCancer Drug Resistance · 2025
  45. Cisplatin resistance in head and neck squamous cell carcinoma is linked to DNA damage response and cell cycle arrest transcriptomics rather than poor drug uptakeCancer Drug Resistance · 2025
  46. Molecular targeting of the deubiquitinase USP14 to circumvent cisplatin resistance in ovarian carcinoma and identification of novel inhibitorsCancer Drug Resistance · 2025
  47. Distinct adaptive strategies to cisplatin, vinblastine and gemcitabine in a panel of chemoresistant bladder cancer cell linesCancer Drug Resistance · 2025
  48. Integrating genomic mutations and tumor-infiltrating lymphocytes improves prediction of response to trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancerCancer Drug Resistance · 2025
  49. Lactylation: a novel driver of drug resistance in the tumor microenvironmentCancer Drug Resistance · 2025
  50. Corosolic acid increases the therapeutic effect of cisplatin on gastric cancer by regulating Gpx4-dependent ferroptosisCancer Drug Resistance · 2025